Medpace Holdings Inc. (MEDP)
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Medpace Holdings Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medpace: Buy The Short-Term Pain For Long-Term Gains
Medpace Holdings' stock fell after Q3 earnings due to revenue growth concerns and a low book-to-bill ratio, but the long-term prospects remain strong. Medpace offers full-service clinical trial management, catering mainly to small biopharma companies lacking trial expertise, making it a stand-out player in the CRO market. Despite short-term revenue growth issues, Medpace's financials are impressive, with high profitability, no debt, and strong returns on capital, justifying a Buy rating.
MEDP Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm
RADNOR, PA / ACCESSWIRE / October 25, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace"). On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024.
Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP
/ ACCESSWIRE / October 23, 2024 / NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Medpace Holdings, Inc. (MEDP) Q3 2024 Earnings Call Transcript
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q3 2024 Earnings Conference Call October 22, 2024 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Eric Coldwell - Baird Ann Hynes - Mizuho Dan Leonard - UBS Justin Bowers - DB Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Operator Good day, ladies and gentlemen, and welcome to the Medpace Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Why Is Medpace Stock Diving On Tuesday?
Medpace Holdings, Inc. MEDP shares are trading lower on Tuesday after reporting its third-quarter financial results yesterday.
Medpace Stock Drops. Biotech's Doldrums Are to Blame.
The drug-testing company saw higher-than-normal levels of cancellations in the third quarter.
Medpace (MEDP) Tops Q3 Earnings Estimates
Medpace (MEDP) came out with quarterly earnings of $3.01 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.22 per share a year ago.
Medpace Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – MEDP
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Medpace Holdings, Inc. (MEDP) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
